Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.61 |
| ▸ | CALCR | P30988 | 3/20 | 0.58 |
| ▸ | NPY2R | P49146 | 7/20 | 0.57 |
| ▸ | NPY4R | P50391 | 7/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.57 |
| ▸ | NPY1R | P25929 | 5/20 | 0.57 |
| ▸ | GLP1R | P43220 | 3/20 | 0.56 |
| ▸ | GCGR | P47871 | 3/20 | 0.56 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.55 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSH | P09668 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | TFPI | P10646 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30511758 | 0.91 | CALCR (0.58) | APLNRCALCRNPY2RNPY4RNPY5R | |
| SCHEMBL31182924 | 0.90 | GLP1R (0.61) | APLNRCALCRNPY2RNPY4RNPY5R | |
| SCHEMBL31182551 | 0.90 | CALCR (0.68) | APLNRCALCRNPY2RNPY4RNPY5R | |
| SCHEMBL30276691 | 0.90 | CALCR (0.68) | APLNRCALCRNPY2RNPY4RNPY5R | |
| SCHEMBL30495679 | 0.90 | CALCR (0.55) | APLNRCALCRGLP1RGCGRCRHR1 | |
| SCHEMBL30446021 | 0.90 | CALCR (0.68) | APLNRCALCRGLP1RGCGRCRHR1 | |
| SCHEMBL31182700 | 0.89 | CALCR (0.68) | APLNRCALCRNPY2RNPY4RNPY5R | |
| SCHEMBL30607293 | 0.89 | APLNR (0.59) | APLNRCALCRCTSLCTSHCTSS | |
| SCHEMBL30567004 | 0.89 | CALCR (0.61) | APLNRCALCRNPY2RNPY4RNPY5R | |
| SCHEMBL30262103 | 0.89 | F2 (0.60) | CALCRNPY2RNPY4RNPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297227-B2 | Method for extracting target protein from biological sample and method for analyzing target protein | MEDIFORD CORPORATION (JP) | 2025-05-13 | — | — | US | claimed |
| US-11241395-B2 | Use of procalcitonin (PCT) in risk stratification and prognosis of patients with a primary, non-infectious disease | B.R.A.H.M.S. GMBH (DE) | 2022-02-08 | — | — | US | claimed |
| US-12638445-B2 | Fluid transfer devices with integrated flow-based assay and methods of using the same | Magnolia Medical Technologies, Inc. (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4718076-A2 | WORKFLOW FOR RISK ASSESSMENT AND PATIENT MANAGEMENT USING PROCALCITONIN AND MIDREGIONAL-PROADRENOMEDULLIN | B.R.A.H.M.S GmbH (DE) | 2026-04-01 | — | — | EP | disclosed |
| EP-4717174-A2 | FLUID TRANSFER DEVICES WITH INTEGRATED FLOW-BASED ASSAY | Magnolia Medical Technologies, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260083840-A1 | METHODS FOR ABLATING MYELOID DERIVED SUPPRESSOR CELLS USING NEO-201 ANTIBODY | PREC BIOLOGICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4073515-B1 | FLUID TRANSFER DEVICES WITH INTEGRATED FLOW-BASED ASSAY | MAGNOLIA MEDICAL TECHNOLOGIES INC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3729101-B1 | WORKFLOW FOR RISK ASSESSMENT AND PATIENT MANAGEMENT USING PROCALCITONIN AND PROADRENOMEDULLIN | BRAHMS GMBH (DE) | 2026-03-18 | — | — | EP | disclosed |
| EP-4710108-A1 | MID-REGIONAL PRO-ADRENOMEDULLIN IMMUNOASSAY WITH MONOCLONAL ANTIBODIES | B.R.A.H.M.S GmbH (DE) | 2026-03-18 | — | — | EP | disclosed |
| US-20260056215-A1 | Pro-ADM for Prognosis of Trauma-Related Complications in Polytrauma | B.R.A.H.M.S GMBH (DE) | 2026-02-26 | — | — | US | disclosed |
| US-12560620-B2 | Pro-ADM for prognosis of trauma-related complications in polytrauma patients | B.R.A.H.M.S GMBH (DE) | 2026-02-24 | — | — | US | disclosed |
| US-20220143148-A1 | COMPOSITIONS AND METHODS FOR MODULATING CGRP SIGNALING TO REGULATE INTESTINAL INNATE LYMPHOID CELLS | THE BROAD INSTITUTE, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11327082-B2 | Proadrenomedullin as a marker for abnormal platelet levels | B.R.A.H.M.S GMBH (DE) | 2022-05-10 | — | — | US | disclosed |
| EP-3682241-B1 | PCT AND PRO-ADM AS MARKERS FOR MONITORING ANTIBIOTIC TREATMENT | BRAHMS GMBH (DE) | 2022-03-30 | — | — | EP | disclosed |
| EP-3971573-A1 | PROADRENOMEDULLIN AS A MARKER FOR ABNORMAL PLATELET LEVELS | B.R.A.H.M.S GmbH (DE) | 2022-03-23 | — | — | EP | disclosed |
| EP-3971572-A1 | PROADRENOMEDULLIN AS A MARKER FOR ABNORMAL PLATELET LEVELS | B.R.A.H.M.S GmbH (DE) | 2022-03-23 | — | — | EP | disclosed |
| US-20220073944-A1 | MULTIMERIC CODING NUCLEIC ACID AND USES THEREOF | TRANSLATE BIO, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220071905-A1 | PEG LIPIDOID COMPOUNDS | TRANSLATE BIO, INC. | 2022-03-10 | — | — | US | disclosed |
| EP-3682247-B1 | PROADRENOMEDULLIN AS A MARKER FOR ABNORMAL PLATELET LEVELS | BRAHMS GMBH (DE) | 2022-02-09 | — | — | EP | disclosed |
| US-11241395-B2 | Use of procalcitonin (PCT) in risk stratification and prognosis of patients with a primary, non-infectious disease | B.R.A.H.M.S. GMBH (DE) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083840-A1 | METHODS FOR ABLATING MYELOID DERIVED SUPPRESSOR CELLS USING NEO-201 ANTIBODY | CD47, SIGLEC9, LGALS1 | APLNR 1104/4885CALCR 2585/4885NPY2R 4316/4885 |
| US-20220073944-A1 | MULTIMERIC CODING NUCLEIC ACID AND USES THEREOF | NSUN3, TRDMT1, NSUN2 | APLNR 247/4885CALCR 1007/4885NPY2R 2426/4885 |
| US-12560620-B2 | Pro-ADM for prognosis of trauma-related complications in polytrauma patients | CALCA, MYADM, CALCB | APLNR 590/4885CALCR 10/4885NPY2R 2923/4885 |
| US-20260056215-A1 | Pro-ADM for Prognosis of Trauma-Related Complications in Polytrauma | MYADM, SERPINC1, PROKR1 | APLNR 224/4885CALCR 278/4885NPY2R 1875/4885 |
| US-20220071905-A1 | PEG LIPIDOID COMPOUNDS | HDLBP, LIPG, ABCB4 | APLNR 1685/4885CALCR 4763/4885NPY2R 4154/4885 |
| US-12638445-B2 | Fluid transfer devices with integrated flow-based assay and methods of using the same | SLCO1B3, SLCO1A2, SLCO1B1 | APLNR 2701/4885CALCR 1007/4885NPY2R 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.